Services on Demand
Journal
Article
Related links
Share
Veterinaria (Montevideo)
Print version ISSN 0376-4362On-line version ISSN 1688-4809
Abstract
YANESELLI, Kevin; ALGORTA, Agustina and MAISONNAVE, Jacqueline. Case reports on veterinary regenerative medicine: Use of platelet-rich plasma (PRP) at the national level. Veterinaria (Montev.) [online]. 2025, vol.61, n.223, e501. Epub Jan 01, 2025. ISSN 0376-4362. https://doi.org/10.29155/vet.61.223.2.
The utilization of platelet-rich plasma (PRP) and other platelet-derived products (PDP) has garnered significant attention within both the realms of human and veterinary medicine. The interest on PRP and PDP derives from the potential to facilitate tissue regeneration and aid in the healing of challenging lesions, attributed to its concentration of growth factors. The Veterinary Medicine School provides the Veterinary Regenerative Medicine (VRM) service, dedicated to advancing new therapeutic modalities for veterinary professionals. This study aims to delineate the casuistry of PDP requests to the VRM service by professionals between 2018 and 2022. Analysis of data obtained from the VRM service revealed a total of 55 requests for PDP during the specified period. Predominantly, these requests were for orthopedic pathologies (73 %), with dermatological and dental pathologies each comprising less than 10 % of requests. Likewise, autologous PRP was the most requested (93 %), in a smaller proportion (<5 %) platelet-rich fibrin (PRF) was requested. The predominant species requested was canine (56 %) followed by equine (38 %) and only 2 % feline. The age range of the animals with the highest frequency of requests to the service was between 5 and 10 years (44 %). In summary, veterinary professionals in Uruguay, frequently ask the VRM service for autologous PRP. Orthopedic pathologies emerged as the most common indication for PRP application during the study period, with the service primarily sought after for canine and equine patients.
Keywords : Canine; Equine; Platelet-rich plasma; Platelet-derived products; Regenerative medicine.